Jennifer Fulk was named Chief Financial Officer of Kura Oncology, Inc., effective September 8, 2026. As of November 6, 2026, Kura Oncology, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 8, 2026, naming 1 appointment (Form 8-K, September 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kura Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kura Oncology, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-08. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Kura Oncology, Inc. files it.
Also on the record for Kura Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Montanova Capital, LLC | 9.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.23% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.01% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 5.67% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 5.37% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 7.14% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kura Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kura Oncology, Inc. and the records around it.
Kura Oncology, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Montanova Capital, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Kura Oncology, Inc.
Get an email when Kura Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kura Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kura Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kura Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-08 | In | Chief Financial Officer | 2026-09-08 | 8-K, 2026-09-08 |
Who leads Kura Oncology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jennifer Fulk, appointed, effective 2026-09-08 (filed 2026-09-08).
New leaders reset buying decisions — get the Full Report on Kura Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Kura Oncology, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Kura Oncology, Inc.Every change, in the filing's words
Appointed: Jennifer Fulk, Chief Financial Officer, effective 2026-09-08
(c) Effective as of September 8, 2026, the Board of Directors (the "Board") of Kura Oncology, Inc. (the "Company") appointed Jennifer Fulk as the Company's Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such role).
- Ms. Fulk, age 49, served as Chief Financial Officer of Soleno Therapeutics, Inc., from March 2026 to May 2026.
- Previously, she served as Chief Operating Officer and Chief Financial Officer of 120Water, Inc., from September 2024 to October 2025 and as Chief Financial Officer of Talkspace, Inc., a publicly traded virtual behavioral healthcare company, from July 2021 to May 2024.
- Prior to that, Ms. Fulk spent more than 15 years at Eli Lilly and Company in finance executive roles, including as Chief Financial Officer, U.S. Bio-Medicines; Vice President, Investor Relations; Vice President, Global Finance and Integration, Elanco; and Chief Financial Officer, Lilly Germany, Austria, and Switzerland.
- In these roles, she led global finance teams, supported commercial and research and development organizations, and partnered closely with executive leadership on strategy, operations and capital markets engagement.
- Ms. Fulk earned her Bachelor of Science in Information Systems and a Master of Business Administration from Indiana University.
- In connection with Ms. Fulk's appointment, the Company entered into an employment agreement with Ms. Fulk on September 8, 2026 (the "Fulk Agreement").
Tools for this story
Each opens in a new tab, filled in for Kura Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.